×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AKTX – akari therapeutics plc - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AKTX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/4
09:00 am
aktx
Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment
High
Report
Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment
11/25
09:00 am
aktx
Akari Therapeutics Announces Release of the Next CEO Corner Segment
Medium
Report
Akari Therapeutics Announces Release of the Next CEO Corner Segment
11/18
08:35 am
aktx
Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer
Medium
Report
Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer
11/10
08:30 am
aktx
Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors
Low
Report
Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors
11/4
09:25 am
aktx
Akari Therapeutics’ Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available
High
Report
Akari Therapeutics’ Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available
10/30
08:35 am
aktx
Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP
Low
Report
Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP
10/22
09:05 am
aktx
Akari Therapeutics Announces Launch of CEO Corner Platform
Medium
Report
Akari Therapeutics Announces Launch of CEO Corner Platform
10/15
08:30 am
aktx
Akari Therapeutics Announces $2.5 Million Registered Direct Offering
Low
Report
Akari Therapeutics Announces $2.5 Million Registered Direct Offering
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
8/14
Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)
30.9%
1/10 Akari Therapeutics Announces Positive Interim Data from Phase III Paroxysmal Nocturnal Hemoglobinuria (PNH) Study 25.6%
8/29 Akari Therapeutics Reports Second Quarter 2019 Financial Results And Highlights Recent Clinical Progress 12.2%
2/20 Akari Therapeutics, Plc Announces Private Placement 8.2%
11/27 Form 6-K Akari Therapeutics Plc For: Nov 27 7.9%
3/26 Form F-3 Akari Therapeutics Plc 5.7%
6/28 Form 6-K Akari Therapeutics Plc For: Jun 28 5.4%
12/5 Regeneron's pozelimab shows positive effect in PNH study [Seeking Alpha] 5.3%
12/2 Akari Therapeutics Announces Pivotal Phase III Trial Design of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA), Following FDA Meeting 4.9%
9/13 Akari Therapeutics PLC (NASDAQ: AKTX) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong sell" rating. 4.8%
1/10 Akari Therapeutics Announces Positive Interim Data from Phase III Paroxysmal Nocturnal Hemoglobinuria (PNH) Study 25.6%
8/29 Akari Therapeutics Reports Second Quarter 2019 Financial Results And Highlights Recent Clinical Progress 12.2%
2/20 Akari Therapeutics, Plc Announces Private Placement 8.2%
11/27 Form 6-K Akari Therapeutics Plc For: Nov 27 7.9%
3/26 Form F-3 Akari Therapeutics Plc 5.7%
6/28 Form 6-K Akari Therapeutics Plc For: Jun 28 5.4%
12/5 Regeneron's pozelimab shows positive effect in PNH study [Seeking Alpha] 5.3%
12/2 Akari Therapeutics Announces Pivotal Phase III Trial Design of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA), Following FDA Meeting 4.9%
9/13 Akari Therapeutics PLC (NASDAQ: AKTX) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong sell" rating. 4.8%
TOP News Decliners
5/1
Akari Therapeutics Announces Positive Topline Results from Fully Recruited Phase II Study of Nomacopan in Bullous Pemphigoid Patients
-24.4%
3/13 Akari Therapeutics PLC (NASDAQ: AKTX) had its price target lowered by analysts at B. Riley from $7.00 to $5.00. They now have a "buy" rating on the stock. -15.4%
4/2 Akari Therapeutics PLC (NASDAQ: AKTX) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $5.00 price target on the stock. -15.2%
9/13 Akari Therapeutics’ Nomacopan Granted U.S. Orphan Drug Designation for Bullous Pemphigoid -12.8%
10/10 Akari Therapeutics Announces Positive Phase II Clinical Data in Orphan Blistering Skin Disease Bullous Pemphigoid at the 28th EADV Congress -12.0%
8/30 Thinking about buying stock in Aurora Cannabis, Akari Therapeutics, Big Lots, Campbell Soup, or Walt Disney Co? -11.1%
3/11 Form D Akari Therapeutics Plc -10.5%
8/9 Akari Therapeutics announces new data demonstrating synergistic benefits of nomacopan’s bifunctional C5 and LTB4 inhibitory activity in pemphigoid disease -9.8%
12/23 Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) Following the Opening of its IND -8.9%
9/3 Akari Therapeutics to Participate in Citi and H.C. Wainwright Conferences in Early September -8.2%
3/13 Akari Therapeutics PLC (NASDAQ: AKTX) had its price target lowered by analysts at B. Riley from $7.00 to $5.00. They now have a "buy" rating on the stock. -15.4%
4/2 Akari Therapeutics PLC (NASDAQ: AKTX) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $5.00 price target on the stock. -15.2%
9/13 Akari Therapeutics’ Nomacopan Granted U.S. Orphan Drug Designation for Bullous Pemphigoid -12.8%
10/10 Akari Therapeutics Announces Positive Phase II Clinical Data in Orphan Blistering Skin Disease Bullous Pemphigoid at the 28th EADV Congress -12.0%
8/30 Thinking about buying stock in Aurora Cannabis, Akari Therapeutics, Big Lots, Campbell Soup, or Walt Disney Co? -11.1%
3/11 Form D Akari Therapeutics Plc -10.5%
8/9 Akari Therapeutics announces new data demonstrating synergistic benefits of nomacopan’s bifunctional C5 and LTB4 inhibitory activity in pemphigoid disease -9.8%
12/23 Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) Following the Opening of its IND -8.9%
9/3 Akari Therapeutics to Participate in Citi and H.C. Wainwright Conferences in Early September -8.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: